根据 Insight 数据库「中国上市策略 & 时长预测」模块， 2025 年预计将有 40 款抗肿瘤新药首次在国内获批上市。本文将节选其中 15 个潜在重磅抗肿瘤新药信息进行分享，仅供读者参阅（以下排名不分先后）。强生：塔奎妥单抗 CD3 × ...

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...

Tubulis continues expansion of its clinical pipeline with a second ADC drug candidate entering the clinic TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed based ...

Adc Therapeutics SA stock has reached a 52-week low, trading at $1.61, as the company faces a challenging market environment. According to InvestingPro analysis, the stock's RSI indicates oversold ...

ADC Therapeutics SA股票在公司面临市场挑战的环境下触及52周新低，交易价格为1.61美元。根据 InvestingPro ...

TUB-030 consists of a humanized, Fc-silenced IgG1 antibody targeting 5T4 equipped with Tubulis’ proprietary Tubutecan technology, which is based on P5 conjugation chemistry and the topoisomerase-1 ...

DATROWAY is comprised of a humanized antiTROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an ...

These new constructs will Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer Strong efficacy for FRA-H in KB and ...

Expert Rev Anticancer Ther. 2012;12(10):1327-1336. From a clinical perspective, it is intriguing to see that the issue of 'lines of therapy' is being discussed in a disease as devastating as ...

A Grothey received research support from Genentech and Bayer, and serves as an uncompensated consultant for Genentech, Bayer, Eli-Lilly, Regeneron, and Sanofi. The authors have no other relevant ...